Agilent to Announce First-Quarter Fiscal Year 2025 Financial Results on Feb. 26
Agilent Technologies Inc. (
NYSEA) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST.
Agilent Automated Workflows at SLAS2025: Connecting with Confidence
Agilent Technologies Inc. (
NYSEA) announced today that it will feature new automated laboratory workflow solutions at the SLAS2025 International Conference & Exhibition being held January 25-29, at the San Diego Convention Center in California. Agilent is a leader in advancing automation solutions to help customers optimize lab performance, efficiency, and reproducibility across their entire pipeline, from research and drug discovery to development and manufacturing processes.
Agilent Presents Solutions Innovation Research Awards to Aarhus University, University of Graz, and Imperial College London Scientists
Agilent Technologies Inc. (
NYSEA) today announced Solutions Innovation Research Awards (SIRA) have been presented to Professor Anders Bentien of Aarhus University, Professor Walter Gössler of University of Graz, and Professor Gregory Offer of Imperial College London. These separate awards recognize their outstanding contributions to battery research.
YLCHAT Triumphs on Nasdaq: A Digital Revolution in Financial IntegrationIn a landmark moment for the financial technology sector, YLCHAT, an innovative internet-integrated financial platform, made a dazzling debut on the Nasdaq screen today, signaling a new era in how global markets are connected and managed.
Agilent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Agilent Technologies Inc. (
NYSEA) today announced that CEO Padraig McDonnell and CFO Bob McMahon will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 14, 2025, at 9:45 a.m. Pacific time.
Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification
Agilent Technologies Inc. (
NYSEA) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx (Code SK005). This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR) 1. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution.
Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results
Agilent Technologies Inc. (
NYSEA) today reported revenue of $1.70 billion for the fourth quarter ended October 31, 2024, an increase of 0.8% reported and a decline of 0.3% core(1) compared to the fourth quarter of 2023.
Agilent Announces New Organizational Structure to Support its Market-Focused Strategy
Agilent Technologies Inc. (
NYSEA) today announced a new organizational structure to accelerate the company’s operational transformation to drive higher growth through a market-focused, customer-centric enterprise strategy. The new structure, including new leadership roles, takes effect immediately.
Agilent Increases Cash Dividend to 24.8 Cents per Share
Agilent Technologies, Inc. (
NYSEA) today announced the company has increased its quarterly dividend to 24.8 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 22, 2025, to all shareholders of record as of the close of business on Dec. 31, 2024.
Agilent 2024 Early Career Professor Award Presented to Adeyemi Adeleye
Agilent Technologies Inc. (
NYSEA) announced today that Adeyemi Adeleye, Ph.D., has received the Agilent 2024 Early Career Professor Award for his contribution to environmental health and sustainability, developing green analytical technologies, methods, or laboratory working environments. Dr. Adeleye is an assistant professor in the Department of Earth and Environmental Engineering at Columbia University.
Agilent Ranks No. 11 on Fortune’s List of Best Workplaces in the World
Agilent Technologies Inc. (
NYSEA) today announced the company has been named to Fortune’s list of Best Workplaces in the World, ranking no. 11 among 25 companies.
Agilent Announces the Innovative Mito-rOCR Assay Kit for Mitochondrial Research
Agilent Technologies Inc. (
NYSEA) announces the new Mito-rOCR Assay Kit. This easy and streamlined end-to-end solution makes sophisticated analysis of mitochondrial function available to researchers of all skill levels. With this cost-effective and versatile kit, researchers can easily incorporate functional assessment of relative mitochondrial respiration into their cell physiology and disease pathology studies.
Agilent Presents Solutions Innovation Research Awards to Institut National de la Recherche Scientifique and University of Southern California Scientists
Agilent Technologies Inc. (
NYSEA) today announced that Professor Isabelle Plante at Institut National de la Recherche Scientifique (INRS), and Professor Bangyan Stiles at the University of Southern California (USC) are recipients of an Agilent Solutions Innovation Research Award (SIRA). The honorees will receive separate awards on behalf of their institutions in recognition of their research in cell and gene therapy.
Agilent Revolutionizes HPLC with the Launch of the Agilent Infinity III LC Series
Agilent Technologies Inc. (
NYSEA) today announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions. These are the first HPLC systems on the market to feature the new Agilent InfinityLab Assist Technology, offering enhanced, built-in system assistance capabilities. This technology allows labs to focus more on achieving results rather than on daily operation and maintenance tasks.
Agilent to Announce Fourth-Quarter Fiscal Year 2024 Financial Results on Nov. 25
Agilent Technologies Inc. (
NYSEA) will release financial results for the fourth quarter of fiscal year 2024 after the stock market closes on Monday, Nov. 25. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST.
Agilent to Host Analyst and Investor Day on Dec. 17, 2024
Agilent Technologies Inc. (
NYSEA) will host an Analyst and Investor Day in New York City on Tuesday, Dec. 17, at 10 a.m. ET.
Agilent Completes Acquisition of BIOVECTRA
Agilent Technologies Inc. (
NYSEA) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
Agilent Announces Cash Dividend of 23.6 Cents per Share
Agilent Technologies, Inc. (
NYSEA) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of business on Oct. 1, 2024.
Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine
Agilent Technologies Inc., (
NYSEA) today announced the launch of its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, following receipt of California State clinical laboratory license and Clinical Laboratory Improvement Amendments (CLIA) certificate of compliance.
Agilent Technologies Thrives From the Forever Chemicals CrackdownAgilent Technologies Inc. (
NYSEA) is a diversified global leader in the life sciences, diagnostics and applied chemical markets.
Agilent Reports Third-Quarter Fiscal Year 2024 Financial Results
Agilent Technologies Inc. (
NYSEA) today reported revenue of $1.58 billion for the third quarter ended July 31, 2024, a decline of 5.6% reported and 4.4% core(1) compared to the third quarter of 2023.
Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance
Agilent Technologies Inc., (
NYSEA) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column technology. Agilent has a 50-year history of innovation in gas chromatography, continually setting the standard for GC column performance. The new Agilent J&W 5Q GC/MS columns combine Agilent’s industry-recognized ultra-inert performance and ultra-low-bleed technology, delivering unmatched performance and durability for the most demanding applications.
Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy
Agilent Technologies Inc., (
NYSEA) today announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovial sarcoma who may be eligible for treatment with TECELRA® (afamitresgene autoleucel, also known as afami-cel or ADP-A2M4), a MAGE-A4-directed engineered TCR T-Cell therapy.
Agilent Acquires Sigsense, Creator of AI-Enabled Lab Operations Technology
Agilent Technologies Inc. (
NYSEA) today announced it has acquired Sigsense Technologies, a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help optimize lab operations. Financial terms of the acquisition were not disclosed.
Agilent to Acquire North American CDMO BIOVECTRA
Agilent Technologies Inc. (
NYSEA) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million.
